




Our earlier reports



Not all as rosy as it appears to be!

- Despite expectations of a stronger 2H, performance has remained weak, with aggregate revenue, EBITDA, and PAT declining sequentially in FY24 and continuing the trend in FY25. The coverage universe of 12 companies performed worse than the broader sector, with significant YoY and QoQ declines across key financial metrics.
- Despite volume growth, pricing pressure kept margins subdued, with EBITDAM declining 150bp QoQ and 70bp YoY for 63 companies, and 130bp YoY for our coverage universe. Normalized other income led to a PAT margin contraction, with 43% of the companies analyzed experiencing a QoQ decline, and a 200bp drop for the coverage universe.
- EBITDA and PAT for the coverage universe missed estimates in 3QFY25, leading to downward revisions for seven companies in our universe, while three companies saw upward revisions. Management anticipates a demand recovery going forward, with capacity expansions on track. However, competitive pressures and feedstock costs pose risks, and FY26 earnings estimates remain at risk of further downgrades.

Sequential decline a worry

- For the past two years, companies have been projecting that 2H would be better than 1H, but this has not proven to be the case. For instance, in FY24, aggregate revenue was INR897b in 2H vs. INR899b in 1H, with EBITDA at INR108b in 2H vs. INR127b in 1H for the 63 companies we analyzed. EBITDAM was 12.1% vs. 14.1% in 1HFY24. Aggregate revenue/ EBITDA/ PAT for our coverage universe declined 2%/ 14%/22% in 2H vs. 1HFY24.
- A similar story seems to be unfolding in FY25, with all parameters in a declining trend on a sequential basis in 3QFY25. While the performance may seem encouraging on a YoY basis, it is important to recognize that the corresponding period had its own share of challenges, due to which the base effect could make the numbers appear to be on an uptrend. Aggregate revenue/ EBITDA/ PAT was down 2%/12%/7% QoQ for the 63 companies we analyzed.
- Our coverage universe of 12 companies is facing a more challenging situation than the overall sector, with aggregate revenue/EBITDA/PAT declining 5%/12%/24% QoQ. EBITDA/PAT also declined 1%/12% YoY for our coverage universe. In 3QFY25, revenue/EBITDA/PAT for our coverage universe declined 3%/24%/38%, compared to 3QFY23. Revenue/EBITDA/PAT declined for 50%/75%/83% of the companies in our coverage universe in our coverage universe w.r.t. 3QFY23.

Margin pressure persists

- While companies have reported sequential volume growth, pricing pressure continues to persist, keeping margins subdued. Among the 63 companies we analyzed in 3QFY25, 48% reported a QoQ decline in EBITDAM, while 52% of companies reported a YoY decline. The aggregate EBITDAM decline was 70bp YoY and 150bp QoQ. For our coverage universe, the decline was 130bp each for YoY and QoQ.
- Other income was also higher than expected in 1HFY25, which led to earnings being slightly on the higher side. However, this has now returned to normalized levels, resulting in a contraction in PAT margin in 3QFY25. Among the 63

Aman Chowdhary - Research Analyst (Aman.Chowdhary@MotilalOswal.com)

Sumant Kumar - Research Analyst (Sumant.Kumar@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

companies analyzed, 43% saw a QoQ contraction in their PAT margin, while 44% experienced a YoY decline. The aggregate PAT margin contraction was 40bp QoQ. For our coverage universe, PAT margins contracted 200bp QoQ and 170bp YoY.


Managements optimistic; we remain cautious

- For our coverage universe, revenue was in line with our estimates, while EBITDA and Adj. PAT were below our expectations in 3QFY25. We have revised down our estimates for FINEORG, GALSURF, PI, TTCH, NFIL, NOCIL, and VO after the 3QFY25 earnings. AACL, ATLP, and SRF saw an upward revision in estimates following the 3QFY25 earnings season.
- Managements expect demand recovery going forward, driven by the normalization of both international and domestic markets. Key capacity expansions and greenfield projects are on track, supporting long-term growth across the sector. However, competitive pressures, feedstock costs, and regulatory developments could impact margins and pricing. Capex remains a priority, with investments in new products, technology, and operational efficiency driving future performance.
- The 9MFY25 earnings for our coverage universe declined 12% YoY, while the earnings cut for our coverage universe over 9MFY25 has been to the tune of 18%. At the start of 3Q, our FY26E/27E earnings growth estimates were 34%/22%. However, following the 3Q earnings, the estimates stand at 36%/24%, primarily due to FY25E downgrades after the latest earnings. We believe that our FY26 earnings estimate is currently at risk and could face further downgrades in the coming quarters.

Valuation and view


- **SRF:** The Chemicals business is recovering, with Specialty Chemicals experiencing a demand revival and Fluorochemicals benefiting from export growth, driving an estimated CAGR of ~29% over FY25-27E. Margins are expected to improve due to operating leverage and a higher VAP mix, while the Packaging and Technical Textiles businesses are expected to post ~14% and ~8% CAGR, respectively.
- **ATLP:** End-user demand improved in 9MFY25, and the company is expanding capacities, debottlenecking operations, and increasing its global presence. Key projects, such as the 50ktpa liquid epoxy resins plant and the caustic soda facility, are ramping up, with risks tied to execution delays and margin pressures. We value the stock at 35x Dec'26E EPS to arrive at our TP of INR8,455.
- **VO:** VOPL's new products (MEHQ, Guaiacol, Anisole, 4- MAP, Iso Amylene) are likely to start in 4QFY25, driving growth. Meanwhile, VO, now India's only double-integrated AO maker following the VAPL merger, is expected to grow on the back of robust ATBS demand. We value VO at 45x Dec'26E EPS to arrive at our TP of INR2,600. We reiterate our BUY rating on the stock.

Exhibit 1: The sector trades at 32.8x one-year forward P/E



Source: MOFSL

Exhibit 2: The sector trades at 3.9x one-year forward P/B



Source: MOFSL

Exhibit 3: % of companies (out of 63 analyzed) showing a decline in the below parameters

Parameter	YoY	QoQ	w.r.t. 3QFY23
Revenue	25%	44%	40%
EBITDA	35%	48%	46%
EBITDAM	52%	48%	52%
PAT	37%	48%	46%
PAT margin	44%	43%	56%

*Earnings declared till 13th Feb; Mkt cap of cos. above INR10b
Source: Company, MOFSL

Exhibit 4: % of companies (out of our coverage universe of 12) showing a decline in the below parameters

Parameter	YoY	QoQ	w.r.t. 3QFY23
Revenue	25%	67%	50%
EBITDA	42%	67%	75%
EBITDAM	67%	58%	75%
PAT	42%	75%	83%
PAT margin	58%	67%	83%

Source: Company, MOFSL

Exhibit 5: Aggregate performance for the 63 companies we analyzed in the chemicals sector

Quarter	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	YoY (%)	QoQ (%)	Change w.r.t. 3QFY23 (%)
Aggregate revenue (INR b)	467	491	454	445	429	468	481	493	485	13%	-2%	4%
Aggregate EBITDA (INR b)	77	82	66	61	57	52	68	70	61	7%	-12%	-20%
Aggregate EBITDAM (%)	16.4%	16.7%	14.5%	13.7%	13.3%	11.0%	14.2%	14.1%	12.6%	-0.7%	-1.5%	-3.8%
Aggregate PAT (INR b)	46	49	38	33	29	20	36	35	33	15%	-7%	-28%
Aggregate PAT margin (%)	9.8%	10.0%	8.3%	7.3%	6.7%	4.3%	7.5%	7.2%	6.8%	0.1%	-0.4%	-3.0%

*Earnings declared till 13th Feb; Mkt cap of cos. above INR10b


Source: Company, MOFSL

Exhibit 6: Aggregate performance for the 12 companies under our coverage

Quarter	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	YoY (%)	QoQ (%)	Change w.r.t. 3QFY23 (%)
Aggregate revenue (INR b)	164	168	158	155	150	157	163	168	159	6%	-5%	-3%
Aggregate EBITDA (INR b)	35	37	33	31	27	27	30	31	27	-1%	-12%	-24%
Aggregate EBITDAM (%)	21.5%	21.8%	21.0%	19.8%	18.2%	17.5%	18.3%	18.2%	16.9%	-1.3%	-1.3%	-4.7%
Aggregate PAT (INR b)	22	25	20	18	15	15	16	18	13	-12%	-24%	-38%
Aggregate PAT margin (%)	13.4%	15.0%	12.6%	11.8%	10.2%	9.3%	9.9%	10.5%	8.5%	-1.7%	-2.0%	-4.9%

Source: Company, MOFSL


Exhibit 7: Aggregate revenue for the 63 companies analyzed in 3QFY25



*Earnings declared till 13th Feb; Mkt cap of cos. above INR10b

Source: Company, MOFSL


Exhibit 8: Aggregate EBITDA for the 63 companies analyzed in 3QFY25



*Earnings declared till 13th Feb; Mkt cap of cos. above INR10b

Source: Company, MOFSL


Exhibit 9: Aggregate EBITDAM for the 63 companies analyzed in 3QFY25



*Earnings declared till 13th Feb; Mkt cap of cos. above INR10b

Source: Company, MOFSL


Exhibit 10: Aggregate PAT for the 63 companies analyzed in 3QFY25



*Earnings declared till 13th Feb; Mkt cap of cos. above INR10b

Source: Company, MOFSL

Exhibit 11: Aggregate PAT margin for the 63 companies analyzed in 3QFY25



*Earnings declared till 13th Feb; Mkt cap of cos. above INR10b

Source: Company, MOFSL

Exhibit 12: Outperformers in 3QFY25 in terms of EBITDA (INR m) w.r.t 3QFY23

Co Name	MCap (INR b)	EBITDA (INR m)									Change		
		3Q FY23	4Q FY23	1Q FY24	2Q FY24	3Q FY24	4Q FY24	1Q FY25	2Q FY25	3Q FY25	YoY (%)	QoQ (%)	w.r.t. 3QFY23 (%)
Premier Explosives	21	47	82	167	219	49	151	155	166	155	217	-7	229
BASF India	179	547	1,336	1,978	2,339	2,125	2,456	3,124	2,009	1,704	-20	-15	212
Kiri Industries	30	-171	-48	17	-99	-106	51	167	171	-444	320	-360	160
Tanfac Industries	34	225	258	242	156	146	164	156	272	503	245	85	124
Privi Speciality Chemicals	61	520	321	547	893	900	910	944	1,102	1,128	25	2	117
Fairchem Organics	13	37	192	116	168	198	188	218	88	78	-60	-11	113
Himadri Speciality Chemical	204	1,049	1,256	1,340	1,577	1,739	1,795	1,919	2,081	2,209	27	6	111
Jayant Agro Organics	13	134	244	209	273	181	310	309	283	269	49	-5	101
Heubach Colorants India	13	128	168	259	219	143	100	111	279	250	75	-11	95
Amines & Plasticizers	14	92	139	141	159	170	220	148	163	170	0	4	84
Shree Pushkar Chemicals & Fertilizers	10	131	204	140	140	140	187	177	191	225	61	18	71
DDev Plastiks Industries	25	417	665	539	603	601	838	584	637	704	17	10	69
Oriental Aromatics	10	140	92	9	110	141	209	221	286	226	60	-21	61
Godrej Industries	270	3,732	5,999	2,417	2,655	2,793	559	3,340	5,747	5,968	114	4	60
Vidhi Specialty Food Ingredients	22	126	122	130	137	144	160	141	152	190	32	25	51
S H Kelkar & Company	24	434	455	680	716	768	880	-427	801	637	-17	-21	47
Jyoti Resins and Adhesives	15	163	201	207	214	206	212	234	194	225	9	16	38
Laxmi Organic Industries	55	548	580	773	389	523	900	712	747	748	43	0	36
Gulf Oil Lubricants India	54	900	875	925	1,005	1,104	1,173	1,135	1,074	1,225	11	14	36
Aether Industries	102	473	596	447	460	250	28	402	503	620	149	23	31
Atul	159	1,720	1,494	1,823	1,552	1,517	1,476	2,232	2,427	2,241	48	-8	30
Ultramarine & Pigments	15	292	199	269	242	230	198	265	272	361	57	33	24
Vishnu Chemicals	30	519	612	511	460	409	635	556	452	635	55	41	22
Fineotex Chemical	30	286	327	315	382	404	383	353	364	343	-15	-6	20
Rossari Biotech	35	542	546	577	636	637	636	649	659	648	2	-2	20
Yasho Industries	22	232	264	255	206	223	312	218	280	269	21	-4	16
Neogen Chemicals	48	301	326	281	259	203	358	308	345	346	71	0	15
Linde India	475	1,678	1,864	1,640	1,736	1,862	1,785	1,842	1,788	1,922	3	7	14
Anupam Rasayan India	74	1,113	1,173	1,014	1,075	791	927	532	804	1,243	57	55	12
Grauer & Weil (India)	39	468	293	478	488	546	393	639	427	523	-4	23	12
Epigral	76	1,665	1,546	950	1,077	1,225	1,554	1,763	1,784	1,825	49	2	10
Deepak Fertilizers & Petrochemicals Corp	126	4,612	4,691	2,806	2,861	2,822	4,379	4,644	4,942	4,861	72	-2	5
Alkyl Amines Chemicals	85	695	777	740	483	596	689	791	735	712	19	-3	2

*Earnings declared till 13th Feb; Mkt cap of cos. above INR10b

Source: Company, MOFSL

Exhibit 13: Outperformers in 3QFY25 in terms of EBITDAM (%) w.r.t 3QFY23

Co Name	MCAp (INR b)	EBITDAM (%)									YoY (%)	QoQ (%)	Change w.r.t. 3QFY23 (%)
		3Q FY23	4Q FY23	1Q FY24	2Q FY24	3Q FY24	4Q FY24	1Q FY25	2Q FY25	3Q FY25			
Privi Speciality Chemicals	61	12	8	13	20	22	19	20	21	23	1	2	11
Himadri Speciality Chemical	204	10	12	14	16	17	15	16	18	19	3	1	9
Linde India	475	24	30	23	24	26	28	28	28	32	5	4	8
Jyoti Resins and Adhesives	15	25	31	34	34	33	30	34	30	32	-2	2	7
Tanfac Industries	34	23	22	23	19	17	16	16	24	28	12	4	5
Vidhi Specialty Food Ingredients	22	15	14	16	17	23	20	17	17	19	-4	3	5
Heubach Colorants India	13	7	9	12	11	8	5	6	13	12	4	-1	5
DDev Plastiks Industries	25	6	10	8	9	11	14	9	11	11	0	0	4
Anupam Rasayan India	74	28	24	26	27	27	23	21	27	32	5	5	3
Fairchem Organics	13	4	13	7	11	13	12	13	6	7	-6	1	3
Amines & Plasticizers	14	6	8	10	10	10	12	11	10	9	-1	-1	3
Oriental Aromatics	10	7	5	0	5	7	10	10	12	10	3	-2	3
Godrej Industries	270	10	12	5	7	8	1	8	12	12	5	0	3
BASF India	179	2	4	6	6	6	7	8	5	5	-2	0	3
Yasho Industries	22	16	17	17	15	17	18	13	17	18	1	1	2
Atul	159	14	12	15	13	13	12	17	17	16	2	-2	2
Deepak Fertilizers & Petrochemicals Corp	126	17	17	12	12	15	21	20	18	19	4	1	2
Jayant Agro Organics	13	3	4	4	5	4	5	4	5	5	0	0	2
Shree Pushkar Chemicals & Fertilizers	10	9	11	8	8	8	10	9	11	10	2	-1	2
Gulf Oil Lubricants India	54	12	11	11	13	14	13	13	12	13	0	1	2
Alkyl Amines Chemicals	85	18	19	18	14	19	19	20	18	19	1	1	1
Vishnu Chemicals	30	16	18	17	15	13	21	16	13	17	4	4	1
Laxmi Organic Industries	55	8	8	11	6	8	11	10	10	10	2	0	1
Fineotex Chemical	30	26	24	24	26	29	25	25	25	27	-2	2	1
Neogen Chemicals	48	16	16	17	16	12	18	17	18	17	5	-1	1
Ultramarine & Pigments	15	20	16	21	17	16	15	16	17	20	5	3	1
S H Kelkar & Company	24	11	10	16	16	16	17	-9	15	12	-4	-3	0
Grauer & Weil (India)	39	19	9	24	19	19	12	24	17	19	0	2	0
Jubilant Ingrevia	100	13	9	11	12	10	9	11	12	13	3	1	0

*Earnings declared till 13th Feb; Mkt cap of cos. above INR10b

Source: Company, MOFSL

Exhibit 14: Peer comparison for our coverage universe


Company	Reco	TP (INR)	EPS (INR)			P/E (x)			P/BV (x)			EV/EBITDA (x)			ROE (%)		
			FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
Alkyl Amines	Neutral	1,900	36.2	51.4	67.3	48.2	33.9	25.9	6.4	5.7	5.0	29.7	21.8	16.7	13.9	17.8	20.6
Atul	Buy	8,455	164.2	210.6	251.8	40.0	31.1	26.1	3.5	3.2	2.9	21.5	18.0	15.3	9.1	10.8	11.7
Clean Science	Neutral	1,450	24.0	35.1	43.6	57.8	39.5	31.8	10.3	8.4	6.8	38.4	29.0	23.5	19.4	23.5	23.8
Deepak Nitrite	Neutral	1,835	44.8	66.2	73.4	42.3	28.6	25.8	4.8	4.2	3.7	27.0	18.5	16.7	12.1	15.8	15.3
Fine Organic Industries	Sell	3,570	132.6	118.1	119.3	32.8	36.8	36.4	6.0	5.2	4.6	24.6	27.0	25.9	19.9	15.1	13.4
Galaxy Surfactants	Buy	2,825	83.7	95.5	113.0	29.0	25.4	21.5	3.6	3.2	2.9	18.0	15.6	13.4	13.0	13.4	14.3
Navin Fluorine Int.	Neutral	3,715	59.4	81.0	92.9	65.8	48.3	42.1	7.5	6.7	6.0	39.2	30.2	26.5	11.8	14.6	15.1
NOCIL	Neutral	210	6.8	7.6	11.5	32.9	29.3	19.5	2.1	2.0	1.9	26.7	20.2	13.4	6.6	7.1	10.1
PI Industries	Buy	4,100	109.9	117.9	135.4	32.3	30.1	26.2	5.3	4.5	3.9	23.2	20.5	17.5	17.6	16.2	16.1
SRF	Buy	3,540	42.7	72.0	100.4	66.3	39.3	28.2	6.9	6.1	5.2	32.5	23.0	17.6	10.7	16.4	19.8
Tata Chemicals	Neutral	1,030	17.7	41.3	56.6	53.3	22.9	16.7	1.1	1.1	1.0	13.9	9.8	8.0	2.0	4.7	6.2
Vinati Organics	Buy	2,600	38.9	50.3	60.3	45.0	34.8	29.0	6.5	5.7	4.9	32.2	24.9	20.7	15.4	17.5	18.3

Source: Company, MOFSL

Exhibit 15: The sector is trading at a premium to historical averages, except for the 5-year average

Companies	Current P/E (x)	Average P/E (x)			Prem / Disc P/E (%)		
		15 YR	10 YR	5 YR	15 YR	10 YR	5 YR
Chemicals	32.8	19.2	24.8	33.3	70.5	32.2	-1.4
Alkyl Amines	34.8	25.6	35.3	58.5	36.2	-1.2	-40.4
Atul	31.0	22.6	30.8	43.6	36.9	0.7	-28.9
Clean Science	43.1	NA	62.0	62.0	NA	-30.5	-30.5
Deepak Nitrite	30.9	18.3	22.3	29.0	69.2	38.3	6.7
Fine Organic	35.4	33.1	33.1	34.8	7.1	7.1	2.0
Galaxy Surfactants	20.9	25.6	25.6	27.6	-18.4	-18.4	-24.4
Navin Fluorine	53.6	25.8	36.3	57.7	107.6	47.8	-7.1
NOCIL	27.3	16.0	19.3	25.7	70.7	41.6	6.3
P I Inds.	28.0	26.1	32.4	35.0	7.0	-13.8	-20.1
SRF	41.9	19.6	26.5	35.5	113.2	58.2	17.9
Tata Chemicals	21.4	11.0	14.3	20.7	95.2	49.9	3.3
Vinati Organics	33.2	27.2	34.9	46.5	22.1	-4.8	-28.5

Source: Company, MOFSL

Exhibit 16: The sector is today trading at a discount to what it was trading as on our sector/ respective company IC date

Source: Bloomberg, MOFSL

SRF – Financial summary and assumptions (TP: INR3,540) – BUY

Exhibit 17: Consolidated EBITDA trend




Exhibit 18: Consolidated adjusted PAT trend





Exhibit 19: Financial summary

Y/E MARCH	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Sales	72.1	84.0	124.3	148.7	131.4	145.5	176.6	209.0
EBITDA	14.6	21.3	31.0	36.3	26.6	27.3	38.7	50.7
Adj. PAT	9.2	11.9	18.2	22.7	14.1	12.7	21.4	29.9
Cons. Adj. EPS (INR)	30.9	39.9	61.1	76.2	47.5	42.7	72.0	100.4
EPS Gr. (%)	49.4	29.0	53.1	24.8	(37.7)	(10.1)	68.5	39.5
BV/Sh. (INR)	166	231	288	347	386	411	466	549
Ratios								
Net D:E	0.8	0.4	0.3	0.3	0.4	0.4	0.4	0.3
RoE (%)	20.3	20.1	23.6	24.0	13.0	10.7	16.4	19.8
RoCE (%)	13.3	13.4	17.2	17.9	10.5	9.0	12.8	15.4
Payout (%)	9.6	12.1	26.4	9.9	16.0	37.3	23.6	16.9
Valuations								
P/E (x)	88.8	68.8	45.0	36.0	57.8	64.3	38.1	27.4
EV/EBITDA (x)	58.5	39.5	27.2	23.4	32.2	31.5	22.4	17.1
Div. Yield (%)	0.1	0.2	0.6	0.3	0.3	0.5	0.6	0.6
FCF Yield (%)	(0.1)	0.7	0.4	(0.0)	(0.2)	0.7	0.3	1.1


Source: Company, MOFSL

Exhibit 20: One year forward P/E trades at 40.4x



Source: Company, MOFSL


Exhibit 21: One year forward P/B trades at 6.1x



Source: Company, MOFSL


ATLP – Financial summary and assumptions (TP: INR8,455) – BUY

Exhibit 22: : Expect 13% revenue CAGR over FY24-27



Source: Company, MOFSL

Exhibit 23: EBITDAM to improve




Source: Company, MOFSL

Exhibit 24: Financial summary

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Sales	40.9	37.3	50.8	54.3	47.3	55.2	61.8	68.6
EBITDA	9.0	9.2	9.1	7.7	6.4	9.1	10.8	12.5
PAT	6.7	6.6	6.0	5.1	3.2	4.8	6.2	7.4
EPS (INR)	226.6	222.9	204.2	171.6	110.0	164.2	210.6	251.8
EPS Gr. (%)	53.9	-1.6	-8.4	-16.0	-35.9	49.2	28.3	19.6
BV/Sh.(INR)	1,065.5	1,292.3	1,495.8	1,581.9	1,736.0	1,870	2,043	2,249
Ratios								
Net D:E	0.0	(0.1)	0.0	-0.0	0.0	0.1	0.0	-0.0
RoE (%)	22.8	18.9	14.7	11.1	6.6	9.1	10.8	11.7
RoCE (%)	21.2	17.7	13.7	10.5	6.2	8.3	9.8	11.0
Payout (%)	16.7	8.9	12.2	14.5	18.2	18.2	18.2	18.2
Valuations								
P/E (x)	23.7	24.1	26.3	31.3	48.9	32.8	25.5	21.4
P/BV (x)	5.0	4.2	3.6	3.4	3.1	2.9	2.6	2.4
EV/EBITDA (x)	17.7	17.1	17.5	20.5	25.1	17.7	14.8	12.6
Div. Yield (%)	0.7	0.4	0.5	0.5	0.4	0.6	0.7	0.9
FCF Yield (%)	3.2	2.5	(2.3)	-1.1	1.0	-0.4	2.0	2.7


Source: Company, MOFSL

Exhibit 25: One year forward P/E trades at 28.2x



Source: Company, MOFSL


Exhibit 26: One year forward P/B trades at 2.9x



Source: Company, MOFSL


VO – Financial summary and assumptions (TP: INR2,600) – BUY

Exhibit 27: : Expect 19% revenue CAGR over FY24-27



Source: Company, MOFSL

Exhibit 28: EBITDAM to gradually improve during FY25-27




Source: Company, MOFSL

Exhibit 29: Financial summary

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Sales	10.3	9.5	16.2	20.7	19.0	22.0	27.8	32.3
EBITDA	4.1	3.5	4.3	5.7	4.7	5.7	7.4	8.8
PAT	3.3	2.7	3.5	4.2	3.2	4.0	5.2	6.3
EPS (INR)	32.2	26.0	33.4	40.4	31.2	38.9	50.3	60.3
EPS Gr. (%)	18.2	-19.3	28.7	20.9	-22.8	24.6	29.3	20.0
BV/Sh.(INR)	123.4	148.9	176.3	213.5	237.7	267.9	306.9	353.6
Ratios								
Net D:E	-0.0	-0.0	0.0	0.0	-0.0	0.1	0.1	0.0
RoE (%)	28.6	19.1	20.6	20.7	13.8	15.4	17.5	18.3
RoCE (%)	26.9	18.1	19.5	19.6	13.1	13.7	15.1	16.6
Payout (%)	31.6	23.1	19.4	17.3	22.4	22.4	22.4	22.4
Valuations								
P/E (x)	48.7	60.3	46.9	38.8	50.2	40.3	31.2	26.0
P/BV (x)	12.7	10.5	8.9	7.3	6.6	5.8	5.1	4.4
EV/EBITDA (x)	39.1	46.1	37.5	28.5	34.5	28.9	22.3	18.6
Div. Yield (%)	0.4	0.4	0.4	0.4	0.4	0.6	0.7	0.9
FCF Yield (%)	0.7	1.0	-0.2	1.3	0.7	-0.9	1.6	2.5


Source: Company, MOFSL

Exhibit 30: One year forward P/E trades at 34.4x



Source: Company, MOFSL

Exhibit 31: One year forward P/B trades at 5.6x



Source: Company, MOFSL

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part 1 of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).
MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.

9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263;

www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412. AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dp@motilaloswal.com.